

AMENDMENTS TO THE CLAIMS

Listing of the Claims

The following listing of claims replaces all previous listings or versions thereof:

1. (Currently amended) A composition free of human serum albumin for stabilization of protein agents in pharmaceuticals, the composition comprising the following constituents:
 - a) a surface active substance, preferably a non-ionic detergent-(tenside), and
 - b) a mixture of at least two amino acids, wherein the at least two amino acids are either Glu and Gln or Asp and Asn.
2. (Withdrawn) The composition according to claim 1, further comprising at least one of the following constituents:
 - c) a disaccharide, preferably sucrose (cane sugar), trehalose or lactose,
 - d) ethylenediaminetetraacetic acid (EDTA), preferably in form of one of its salts such as Na₄-EDTA.
3. (Currently amended) The composition according to claim ~~[[1]]~~2 comprising the constituents a), b) and c), the constituents a), b) and d) or the constituents a), b), c) and d).
4. (Previously presented) The composition according to claim 1, wherein the composition is either soluble in aqueous media or is present as aqueous solution.
5. (Previously presented) A pharmaceutical composition comprising a protein agent and a composition free of human serum albumin for stabilization of protein agents in pharmaceuticals, the composition comprising the following constituents:
 - a) a surface active substance, and

- b) a mixture of at least two amino acids, wherein the at least two amino acids are either Glu and Gln or Asp and Asn.
6. (Original) The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is present as a freeze-dried or vacuum-dried powder, which is soluble in aqueous media.
7. (Currently amended) The pharmaceutical composition according to claim 5, wherein the protein agent is a coagulation factor ~~such as factor VIII (the antihemophilic globulin)~~, a cytokine ~~such as a interferon, in particular interferon alpha, beta or gamma~~, an enzyme ~~such as urokinase or streptokinase~~, a plasminogen activator, ~~or an ultra pure neurotoxin~~ [[and]] or a neurotoxin complex, respectively, from *Clostridium botulinum*, in particular from *Clostridium botulinum* type A or B.
8. (Previously presented) The composition for stabilization according to claim 1, wherein the at least two amino acids are (i) aspartic acid, asparagine, glutamic acid; (ii) aspartic acid, asparagine, glutamine; (iii) aspartic acid, glutamic acid, glutamine; (iv) asparagine, glutamic acid, glutamine; or (v) aspartic acid, asparagine, glutamic acid and glutamine.
9. (Previously presented) The pharmaceutical composition according to claim 8, wherein the concentrations of the individual amino acids are in each case 20 to 200 mM, more preferred 20 to 100 mM, in particular 50 mM.
10. (Previously presented) The pharmaceutical composition according to claim 8, wherein the surface active substance is a non-ionic detergent.
11. (Previously presented) The pharmaceutical composition according to claim 10, wherein the non-ionic detergent is a polysorbate ~~such as polysorbate 20 or polysorbate 80 or a poloxamer such as poloxamer 184 or 188.~~

12. (Withdrawn) The pharmaceutical composition according to claim 8, wherein the disaccharide is sucrose, trehalose or lactose.
13. (Currently amended) The pharmaceutical composition according to claim 8, wherein the pH value of the composition in solution is 5.0 to 8.5; ~~in particular 6.0 to 8.0, preferred at 6.0 to 7.0 and 6.5, respectively.~~
14. (Previously presented) The pharmaceutical composition of claim 5, wherein the at least two amino acids are (i) aspartic acid, asparagine, glutamic acid; (ii) aspartic acid, asparagine, glutamine; (iii) aspartic acid, glutamic acid, glutamine; (iv) asparagine, glutamic acid, glutamine; or (v) aspartic acid, asparagine, glutamic acid and glutamine.
15. (New) The pharmaceutical composition according to claim 13, wherein the pH value of the composition in solution is 6.0 to 8.0.
16. (New) The pharmaceutical composition according to claim 13, wherein the pH value of the composition in solution is 6.0 to 7.0.
17. (New) The pharmaceutical composition according to claim 13, wherein the pH value of the composition in solution is 6.5.
18. (New) The pharmaceutical composition according to claim 11, wherein the polysorbate or poloxamer is polysorbate 20, polysorbate 80, or a poloxamer such as poloxamer 184 or 188.
19. (New) The composition of claim 1, wherein the surface active agent is a non-ionic detergent.
20. (New) The composition of claim 19, wherein the non-ionic detergent is tenside.

21. (New) The composition of claim 5, wherein the surface active agent is a non-ionic detergent.
22. (New) The composition of claim 21, wherein the non-ionic detergent is tenside.